

OFFICE OF ENTERPRISE TECHNOLOGY SERVICES

P.O. BOX 119, HONOLULU, HAWAI'I 96810-0119 Ph: (808) 586-6000 | Fax: (808) 586-1922 ETS.HAWAII.GOV

May 7, 2021

The Honorable Ronald D. Kouchi, President, and Members of The Senate Thirty-First State Legislature Hawaii State Capitol, Room 409 Honolulu, Hawaii 96813

The Honorable Scott K. Saiki, Speaker, and Members of The House of Representatives Thirty-First State Legislature Hawaii State Capitol, Room 431 Honolulu, Hawaii 96813

Dear President Kouchi, Speaker Saiki, and Members of the Legislature:

Pursuant to HRS section 27-43.6, which requires the Chief Information Officer to submit applicable independent verification and validation (IV&V) reports to the Legislature within ten days of receiving the report, please find attached the report the Office of Enterprise Technology Services received for the State of Hawaii Department of Health Hawaii BHA Integrated Case Management System Project.

In accordance with HRS section 93-16, this report may be viewed electronically at http://ets.hawaii.gov (see "Reports").

Sincerely,

DOUGLAS MURDOCK Chief Information Officer

State of Hawai'i

Attachment (2)



Hawaii BHA Integrated Case Management System Project – *Phase 3*

Final IV&V Report for the period of March 1 – March 31, 2021

Final submitted: April 12, 2021



Agenda

Executive Summary IV&V Findings & Recommendations

Appendices

- A Rating Scales
- B Inputs
- C Project Trends





Executive Summary

The Project deployed Release 3.13 (R3.13) to production on 3/14/2021. A Root Cause Analysis (RCA) was performed in March to address defects from the previous release. As a result, root causes were identified in the areas of coding, deployment, design, vendor (Microsoft) issues, and requirements. The project identified specific action plans to improve in these areas and will be prioritizing them for execution in April.

Work for R3.14 is wrapping-up in preparation for the upcoming production release starting on 4/9/21.

IV&V continues to monitor high criticality findings for release deployment, regression testing, quality, and Microsoft Issues. We encourage the Project to consider our recommendations to mitigate risk and avoid the reoccurrence of issues in upcoming planned releases.

| Jan | Feb | Mar | Category | IV&V Observations |
|-----|---------------------------|---|--|---|
| Y | Y Sprint perma open (medi | | l • | IV&V continues to recommend the need for skilled MS Dynamics resources to permanently support BHA's technical needs. CAMHD's recruitment activities for their open IT Technician position are still pending. The rating for this category remains Yellow (medium criticality) for the March reporting period. IV&V will continue to monitor this category moving forward. |
| G | G | User Story (US) Validation There are no active findings in User Story (US) Validation category which remains Gree (low criticality) for the March reporting period. IV&V will continue to monitor the US development and validation process in upcoming reporting periods. | | |
| | | | The project deployed R3.13 to production in March. The Project performed an RCA and identified specific action plans to address issues with testing. | |
| R | R | R | Validation | BHA planning efforts to develop automated regression test scripts is on-going. The rating for this category remains Red (high) for the March reporting period. IV&V will continue to monitor this category in upcoming reporting periods. |




Executive Summary

| Jan | Feb | Mar | Category | IV&V Observations |
|-----|-----|-----|--|--|
| R | R | R | Release / Deployment Planning | The criticality rating for this category remains Red (high) for the March reporting period. RCA efforts identified specific actions to improve deployment that are currently being prioritized for execution. IV&V will continue to monitor this category in April. |
| G | G | G | OJT and KT Sessions | The criticality rating for the OJT and KT Sessions category remains Green (low) for the March reporting period with no active findings. |
| G | G | G | Targeted KT | The Targeted KT criticality rating remains Green (low) for the March reporting period. The RSM Team developed system documentation in March for both IDM and Semantics Reporting that will be finalized in April. KT sessions on Semantics Reporting and IDM tools were also conducted in March. IV&V will continue to monitor this category moving forward. |
| G | G | G | Project Performance Metrics | The Project exceeded its performance metrics for R3.13. IV&V will keep the criticality rating for this category a Green (low) and will continue to monitor this category moving forward. |
| G | G | G | Organizational Maturity Assessment | The criticality rating for the Organization Maturity Assessment (OMA) will remain Green (low). Planning efforts for the next OMA (in May) are currently in progress. |
| Y | Y | Y | Project Management | Quality issues that impact DDI activities continue to be an IV&V concern. The Project has conducted a formal RCA based upon R3.12 defects. Several root causes were identified, and corresponding action plans were developed to improve overall quality. BHA Leadership bandwidth also remains a concern for IV&V. The criticality rating for this category remains Yellow (medium) for the March reporting period. IV&V will continue to monitor this category in April. |



Executive Summary

As of the March 2021 reporting period, there are a total of eight open findings – four High Issues and four Medium Risks spread across the Sprint Planning, Release / Deployment Planning, Test Practice Validation, Targeted Knowledge Transfer, and Project Management assessment areas.





Assessment Categories

Throughout this project, IV&V will verify and validate activities performed in the following process areas:

- Sprint Planning
- User Story Validation
- Test Practice Validation
- Release / Deployment Planning
- On-the-Job Training (OJT) and Knowledge Transfer (KT) Sessions
- Targeted Knowledge Transfer (KT)
- Project Performance Metrics
- Organizational Maturity Assessment
- Project Management



Sprint Planning

| # | Key Findings | Criticality Rating | |
|------|--|-----------------------|--|
| 8 | Medium Risk - The BHA Technical Team bandwidth may not be adequate to meet the needs of the project, which could compromise project productivity. BHA continued to take on more lead responsibilities in the areas of user story ownership and performing code reviews during the month of March. CAMHD is hopeful their open IT Technical position will be posted in April. IV&V will continue to monitor this finding. | M | |
| Reco | nmendations | Status | |
| | The Project should investigate mechanisms of increasing the bandwidth of the BHA Technical Team, either by adding resources through new hires, or vendor contracts. | | |
| | e Project should assess, where possible, if there are responsibilities of the BHA Technical Team that can reassigned to other project staff. | In progress | |
| | e Project should evaluate where process inefficiencies can be addressed and streamlined to possibly free the BHA Technical Team's availability. | In progress | |
| | e Project should consider the formation of a first level M&O resource team to triage/address production ects in a timely manner, without disrupting new development work. | In progress | |
| | e Project should consider procurement of an online training toolset to support OCM and technical efforts to set the need for in-person training. | Completed | |



Test Practice Validation

| # | Key Findings | Criticality Rating |
|---|---|-----------------------|
| 2 | High Issue – As a result of regression testing not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production environment. R3.13 was promoted to production on 3/14/2021. The Root Cause Analysis (RCA) effort from R3.12 was completed in March resulting in several recommendations for increasing the quality of Testing. The corresponding RCA Action Plans were expected to be finalized and prioritized by the end of March; however, this has not been completed and the prioritization will be pushed to April. Several of the identified actions will be potentially easy to implement. | B |
| | The BHA Team continued to work with Microsoft during March to plan the level of effort and associated staffing needed to implement automated regression testing using MS DEV OPS. BHA and Microsoft agreed to commence the detailed planning process in May when resource availability syncs up for the two organizations. This functionality is expected to provide repeatable, automated regression testing for CAMHD and DDD in downstream releases. IV&V will continue to monitor this finding. | |

| Recommendations | | |
|--|-----------|--|
| Updating the regression test scripts to ensure consistency with system configuration. | Completed | |
| Modifying release schedules to allow for regression testing timeframes. | Completed | |
| Planning releases by functionality type to avoid unnecessary repetitive work being performed in any given section of the solution. | Completed | |



Test Practice Validation (cont'd)

| Recommendations | Status |
|---|-------------|
| Performing regression testing after every release, or possibly every other release, or potentially tying regression tests to full solution upgrade releases. In addition, consider alternating the DDD and CAMHD scripts every other release. | Completed |
| Modifying regression test scripts to start AFTER case creation, limiting the time it takes to execute. (This recommendation was for a point in time and is no longer valid.) | Completed |
| Modifying the deployment scripts based on information gained from previous release deployments. | Completed |
| Pursuing additional formal training in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. | In Progress |
| Consulting with RSM to determine how the 'interim testing processes' can be improved until such time that automated testing is available for repeatable and complete industry standard regression testing. | Completed |
| Implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. | Completed |
| IV&V recommends performing an RCA in collaboration with RSM for the continued concerns with regression testing efforts. | In Progress |
| Determine if current regression testing timeframes are adequate and if not, add more time to the pre- production regression test efforts for all release deployments. | In Progress |



Release / Deployment Planning

| # | Key Findings | Criticality Rating |
|----|--|-----------------------|
| 19 | High Issue - Due to ongoing deployment processes and technical execution issues, the Project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments. R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort has been pushed to April due to resource constraints. Initial efforts may include providing more details in the SharePoint and deployment checklists coupled with a secondary review process. BHA is considering the procurement of a tool(s) to aid with deployments/releases. This includes the administrative software tool demonstrated by RSM which manages the versions of software and components contained in all environments. IV&V will continue to monitor this finding. | H |

| Recommendations | Status |
|---|-------------|
| Develop a plan to institutionalize the execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. | Open |
| Work in collaboration with RSM to establish a transition plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. | Open |
| As appropriate, consult with RSM on best practices that BHA could employ to support deployment. | In Progress |



Release / Deployment Planning (cont'd)

| Recommendations | Status |
|---|-------------|
| Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. | Completed |
| Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. | In Progress |
| Request the assistance of the RSM Solution Architect in review of deployment scripts as a double check for accuracy and completeness prior to commencing deployment activities. | In Progress |
| Ensure an operational and fully functional test environment is available to effectively conduct end-to-end regression testing prior to deploying a release to production. | Completed |
| The Project Team should consider evaluating potential changes to improve/enhance existing processes and communications to address current release/deployment shortfalls. | In Progress |
| IV&V recommends performing an RCA in collaboration with RSM for the continued concerns surrounding environment differences. | In Progress |
| IV&V recommends updating the Project's Configuration Management Plan to address the current needs of the Project. This should include specific checklists geared at ensuring repeatable promotional processes by DOH. | Open |
| Due to an error prone process of 'cherry picking' what is and what is not ready for deployment, IV&V recommends that DOH and RSM collaborate to determine an improved manner for managing DOH environments. | Open |



Release / Deployment Planning (cont'd)

| # | Key Findings | Criticality Rating |
|----|--|-----------------------|
| 18 | High Issue - Due to consistent technical issues requiring escalation to Microsoft, some project efforts are being delayed. BHA continues to work with Microsoft on technical issues as they arise in the Government Community Cloud (GCC) instance. The issue with fields being locked is still outstanding. IV&V will continue to monitor this finding. | H |

| Recommendations | Status |
|---|-------------|
| IV&V recommends the project to continue to monitor the status of outstanding Microsoft tickets and to escalate the priority of these tickets as deemed necessary. | In Progress |



Project Management

| # | Key Findings | Criticality Rating |
|----|---|-----------------------|
| 10 | Changed from Medium to Low Risk-The COVID-19 pandemic and related "stay at home" order could hinder project activities and negatively impact the project schedule and budget. The Project continued to maintain its ability to operate with staff working remotely, while COVID-related responsibilities continue to grow for CAMHD Leadership. The Governor announced that potential furloughs and/or layoffs of State workers will no longer be necessary based on the signing of the American Rescue Plan. IV&V has reduced the priority of this finding from Medium to Low and will continue to monitor moving forward. | |

| Recommendations | |
|--|-------------|
| IV&V recommends BHA to ramp up efforts to setup, train, and assist stakeholders on remote work devices and tools and make every effort to help them to become highly functional with remote access technology (e.g. MS Teams/Skype). | Completed |
| IV&V recommends the project and DOH create a detailed, documented risk mitigation strategy and plan that is reviewed regularly and revised to address the current state of the COVID-19 threat and related impacts over the next 6 to 12 months. | In Progress |
| IV&V recommends updates to the OCM Plan to include any new activities or updates to planned activities to aid the organization through this COVID-19 situation in the short and long term. | Open |



| # | Key Findings | Criticality Rating |
|----|--|-----------------------|
| 15 | High Issue - Due to multiple quality concerns, the Project may continue to face impactful system defects. R3.13 was promoted to production on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the identified action plan items are considered as potentially easy to implement. IV&V will continue to monitor. | H |

| Recommendations | Status |
|---|-------------|
| Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. | In Progress |
| Perform typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. | In Progress |
| Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. | In Progress |



| Recommendations | |
|---|-------------|
| BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality. | Completed |
| Monitor implemented improvements for effectiveness. | In Progress |
| Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements. | Open |
| IV&V recommends performing an RCA in collaboration with RSM after all future release deployments for continual quality improvement. | In Progress |

| # | Key Findings | Criticality Rating |
|----|---|-----------------------|
| 13 | Changed from Low Risk to Medium Issue – PII/PHI data in non-production environments. There were no substantive changes for this finding in March. Due to resource constraints, establishing a plan for managing PHI/PII data in non-production DOH environments has not yet commenced. Based on continued delays, it remains unclear when this important security mitigation activity will be completed. IV&V has raised the priority of this finding from a Low Risk to a Medium Issue due to delays in resolving this finding. IV&V will continue to monitor. | M |

| Recommendations | |
|---|-------------|
| • IV&V recommends if production data is necessary in any non-production environment that DOH establishes a plan for effectively managing the security of the PII/PHI data, including the potential masking of data. | In Progress |
| IV&V recommends that DOH mitigates this finding by minimizing and/or masking PHI/PII data in designated non-production environments. | In Progress |
| IV&V recommends DOH consider limiting the volume of environments and access necessary to support development work, which should help minimize this risk. | Open |



| # | Key Findings | Criticality Rating |
|----|--|-----------------------|
| 12 | Closed Low Risk – DDD Project resource shortages may have a continued negative effect on user adoption, training, and overall OCM activities. The DDD staff who've been part of the review process are pleased with the quality of the videos produced within the toolset and have determined that the toolset is a very helpful training tool for DDD staff and providers. As such, IV&V is closing this finding. | Closed |

| Recommendations | |
|---|-----------|
| IV&V recommends that BHA does as much as possible within its sphere of influence to increase user adoption and training. This includes procurement of the online training toolsets to offset the need for in-person training, and adding staff as needed to support OCM and technical efforts. | Completed |
| IV&V recommends DOH perform a detailed investigation of the specific variations as to how the system is currently being used by the user community. Consequently, users would be provided with constructive feedback on how the system should be utilized where gaps exist. This will likely lead to additional refresher training to close identified system knowledge gaps. | Completed |



| # | Key Findings | Criticality Rating |
|----|---|-----------------------|
| 14 | Closed Low Risk – Project unable to access activity logs. Per BHA, this finding is no longer an issue and recommends closure. IV&V is closing this finding. | Closed |

| Recommendations | |
|--|-----------|
| IV&V recommends that DHS continues to collaborate with Microsoft until the activity logging feature is | Completed |
| available in all BHA non-production environments. | |



| # | # | Key Findings | Criticality Rating |
|---|---|---|-----------------------|
| 1 | 7 | Changed from Low to Medium Risk - The bandwidth of CAMHD Leadership is being hampered by planning tasks and activities for assessing project expansion to other divisions. CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. | M |

| Recommendations | |
|--|-------------|
| IV&V recommends CAMHD look for opportunities to augment the management staffing for planning Phase 4 and M&O work. | In Progress |



| # | Key Findings | Criticality Rating |
|----|--|-----------------------|
| 20 | Preliminary Concern – The pending RSM contract expiration will require BHA to perform transition of the D365 solution to the State prior to contract end. The RSM contract for Phase 3 is currently planned to complete in September 2021. BHA will need a transition plan to ensure that it has all knowledge transfer and is fully capable of managing all aspects of supporting and maintaining the D365 solution without vendor support until at least the Phase 4 expansion effort is procured and initiated. The Phase 4 effort is currently expected to commence late in the 4th quarter of 2021, or early in the first quarter of 2022. The Phase 4 procurement scope is planned to include additional DD&I activities, as well as M&O support activities. | N/A |



Project Performance Metrics

| Metric | Description | IV&V Observations | IV&V Updates |
|----------|--|---|--------------|
| Velocity | Review and validate the velocity data as reported by the project Verify the project is on pace to hit the total target number of US/USP for Phase 3 | March – Available velocity was estimated at 60 user story points for R3.13, however a total of 89 (148%) USPs were completed and promoted to production. IV&V notes that RSM includes USP counts from Mid Sprint Deployments prior to a planned release as component of the planned release. Overall, the cumulative Phase 3 targeted USPs through R3.13 was planned for 1,098. The cumulative completed USPs total is currently 1,438.3. | N/A |



Project Performance Metrics (cont'd.)

| Metric | Description | IV&V Observations | IV&V Updates |
|----------------|---|---|--------------|
| Defect Metrics | Understand and track the following: Defects by category (bug fixes) US Points assigned to defects in a release vs US Points assigned to planned US in a release | March – R3.13 was comprised of 89 USPs that were released to production. 61% of the total USPs were associated with planned user stories and requests. 39% of the total USPs were associated with defects from the backlog. | N/A |

Organizational Maturity Assessment

Measure IV&V Observations

The Organizational Maturity Assessment (OMA) is updated on a bi-monthly basis. IV&V currently planning for the next OMA in May 2021.



Appendix A: IV&V Rating Scales

Appendix AIV&V Rating Scales

This appendix provides the details of each finding and recommendation identified by IV&V. Project stakeholders are encouraged to review the findings and recommendations log details as needed.

- See Findings and Recommendations Log (provided under separate cover)
- IV&V Assessment Category Rating Definitions

The assessment category is under control and the current scope can be delivered within the current schedule.

The assessment category's risks and issues have been identified, and mitigation activities are effective. The overall impact of risk and issues is minimal.

The assessment category is proceeding according to plan (< 30 days late).

The assessment category is under control but also actively addressing resource, schedule or scope challenges that have arisen. There is a clear plan to get back on track.



The assessment category's risk and/or issues have been identified, and further mitigation is required to facilitate forward progress. The known impact of potential risks and known issues are likely to jeopardize the assessment category. Schedule issues are emerging (> 30 days but < 60 days late).

Project Leadership attention is required to ensure the assessment category is under control.

The assessment category is not under control as there are serious problems with resources, schedule, or scope. A plan to get back on track is needed.



The assessment category's risks and issues pose significant challenges and require immediate mitigation and/or escalation. The project's ability to complete critical tasks and/or meet the project's objectives is compromised and is preventing the project from progressing forward.

Significant schedule issues exist (> 60 days late). Milestone and task completion dates will need to be re-planned. Executive management and/or project sponsorship attention is required to bring the assessment category under control.



Appendix A

Finding Criticality Ratings

| Criticality Rating | Definition |
|-----------------------|--|
| • | A high rating is assigned if there is a possibility of substantial impact to product quality, scope, cost, or schedule. A major disruption is likely, and the consequences would be unacceptable. A different approach is required. Mitigation strategies should be evaluated and acted upon immediately. |
| M | A medium rating is assigned if there is a possibility of moderate impact to product quality, scope, cost, or schedule. Some disruption is likely, and a different approach may be required. Mitigation strategies should be implemented as soon as feasible. |
| • | A low rating is assigned if there is a possibility of slight impact to product quality, scope, cost, or schedule. Minimal disruption is likely, and some oversight is most likely needed to ensure that the risk remains low. Mitigation strategies should be considered for implementation when possible. |





Appendix B

Inputs

This appendix identifies the artifacts and activities that serve as the basis for the IV&V observations.

Meetings attended during the March 2021 reporting period:

- 1. Daily Scrum Meetings (selected)
- 2. Twice Weekly RSM Issues Meeting
- 3. Weekly BHA-ITS Project Status Meeting
- 4. Bi-Weekly Check-in: CAMHD
- Bi-Weekly Check-in: DDD
- 6. BHA IAPDU Planning Meeting
- 7. IV&V Draft IV&V Status Review Meeting with DOH
- IV&V Draft IV&V Status Review Meeting with RSM and DOH
- 9. RCA Log Review Meeting
- 10. RSM Deployment Tool Demo

Eclipse IV&V® Base Standards and Checklists

Artifacts reviewed during the March 2021 reporting period:

- 1. Daily Scrum Notes (selected)
- 2. Twice Weekly Issues Meeting Notes (selected)
- 3. Root Cause Analysis Worksheet
- 4. IDM System Documentation
- 5. Semantics Layer System Documentation



Appendix C: Project Trends

Appendix C Project Trends

| Trend: | Overall | l Projec | t Health | 1 | | | | | | |
|---------------------------------|---------|----------|----------|-----|------|-------|-----|-----|-----|-----|
| Process Area | | | | | 2020 | -2021 | | | | |
| Process Area | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Jan | Feb | Mar |
| User Story Validation | | | | | | | | | | |
| Test Practice Validation | | | | | | | | | | |
| Sprint Planning | | | | | | | | | | |
| Release / Deployment Planning | | | | | | | | | | |
| OJT and KT Sessions | | | | | | | | | | |
| Targeted KT | | | | | | | | | | |
| Project Performance Metrics | | | | | | | | | | |
| Organizational Maturity Metrics | | | | | | | | | | |
| General Project Management | | | | | | | | | | |
| | | | | | | | | | | |
| Total Open Findings | 6 | 6 | 7 | 7 | 10 | 11 | 11 | 10 | 11 | 8 |
| Issue - high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 4 |
| Issue - medium | 0 | 0 | 1 | 2 | 2 | 4 | 4 | 0 | 0 | 0 |
| Issue - low | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Risk - high | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Risk - medium | 2 | 2 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 4 |
| Risk - low | 2 | 1 | 0 | 0 | 0 | 3 | 3 | 4 | 4 | 0 |
| Preliminary Concern | 1 | 1 | 3 | 3 | 5 | 2 | 2 | 0 | 1 | 0 |





Solutions that Matter

| ID No | Identified Date | Title | Observation | Significance | Recommendation | Updates | Process Area | Finding Type | Priority | Status | Closure Reas | Risk Owner |
|-------|-----------------|---|---|---|---|---|-----------------|--------------|----------|--------|---|----------------|
| 1.000 | 12/31/2019 | Detailed investigation into the project's sprint planning processes and adoption of generally accepted agile best practices. | following topics as they relate to Sprint Planning and the project's overall approach to agile software development: - IV&V acknowledges that the project is now planning three sprints outs, however, it appears | is good, the project should be able to identify what feature enhancements will be targeted for each planned release. This roadmap will help the project manage scope and productivity. Relatedly, the "definition done" is an important artifact to ensure that the project is successful. Otherwise, the project will struggle to prioritize requests/enhancements and | As much as possible, the project should identify what feature enhancements will be targeted for each Release and should clearly map out the roadmap out through the last Phase 3 release in September 2020. Additionally, the project should clearly define "Done" to ensure the project team is working towards the same goal and increase opportunities for success. Having a clear "definition of done" will help provide the project with guidance on how to stay within scope. | 01/31/2020 - IV&V is closing this concern, and will be tracking items related to Definition of Done, roadmap, resourcing, and backlog grooming in new, separate findings. | Sprint Planning | Concern | N/A | Closed | Due to multiple new items being tracked at a more granular level, this item has been closed. | V Ramesh |
| 2.000 | 12/31/2019 | As a result of regression testing not being consistently performed, production releases are both breaking and deprecating existing functionality in the production environment. | production specific to Integrated Support and Life Trajectory functionality. DDD has informed IV&V that there are other examples of functionality being | | To address regression testing, the Project should continue to pursue and/or consider: 1. Updating the regression test scripts to ensure consistency with system configuration - Completed 2. Modifying release schedules to allow for regression testing timeframes - Completed 3. Grouping releases by functionality type to avoid unnecessary repetitive work being performed in any given section of the solution - Completed 4. Performing regression testing after every release, or possibly every other release, or potentially tying regression tests to full solution upgrade releases. In addition, consider alternating the DDD and CAMHD scripts every other release - Completed 5. Modifying regression test scripts to start AFTER case creation, limiting the time it takes to execute - Completed 6. Modifying the deployment scripts based on information gained from previous release deployments - Completed | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The Root Cause Analysis (RCA) effort from R3.12 was completed in March resulting in several recommendations for increasing the quality of Testing. The corresponding RCA Action Plans were expected to be finalized and prioritized by the end of March; however, this has not been completed and the prioritization will be pushed to April. Several of the identified actions will be potentially easy to implement. The BHA Team continued to work with Microsoft during March to plan the level of effort and associated staffing needed to implement automated regression testing using MS DEV OPS. BHA and Microsoft agreed to commence the detailed planning process in May when resource availability syncs up for the two organizations. This functionality is expected to provide repeatable, automated regression testing for CAMHD and DDD in downstream releases. IV&V will continue to monitor this finding. 02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release; one was a critical CAMHD defect involving the workflow for | Validation | Issue | High | Open | | D Macdonald |

| 3.000 | 12/31/2019 | Usage of open source JavaScript | IV&V learned in December 2019 | Open source tools and frameworks | IV&V recommends BHA work to | 08/31/2020 - IV&V is unaware of any additional | Targeted KT | Risk | Low | Closed | RSM has | D |
|-------|------------|---|--|---|---|---|---------------------------------|-------|--------|--------|--|----------------|
| 3.000 | 12/31/2019 | framework for development and | that the Calculator 3.0 | offer organizations great | establish a reliable and repeatable | KT gaps being identified by DOH, and as such, is | raigeted Ki | NISK | LOW | ciosea | | Macdonald |
| | | ongoing maintenance of | functionality is built in Vue.JS, an | opportunities to build and | process for keeping abreast of | closing this finding. | | | | | held several | iviacuoliaiu |
| | | Calculator 3.0 requires BHA to | open source JavaScript | configure customized solutions at | communal updates and support | closing this midnig. | | | | | KT sessions | |
| | | take a proactive approach to | | lower costs than through software | opportunities for a new suite of tools - | 07/31/2020 - The Project resolved the majority | | | | | for this | |
| | | support and security. | relatively new, the open source | purchase or licensing. However, | Completed | of the outstanding Calculator 3.0 defects during | | | | | technology | |
| | | | support community is small. | open source tools and frameworks | 1 | July which was implemented in the mid-sprint | | | | | and | |
| | | | IV&V's concerns include: | often do not come with support | targeted KT sessions with RSM on | release on 7/17/2020. The final Calculator 3.0 | | | | | functionality | |
| | | | - The availability of reliable | models, other than those offered | maintaining Calculator 3.0 via a suite of | Knowledge Transfer session was conducted on | | | | | , and DOH | |
| | | | support for Vue.JS | through the tool's community. | tools, and determine what additional | 7/17/2020. IV&V recommends BHA to identify | | | | | staff have | |
| | | | - The project's understanding of | Because of this, the organization | skillsets, training, and/or resources are | and communicate any additional KT gaps to RSM | | | | | stated that it | |
| | | | any known vulnerabilities with | bears the weight of seeking out | needed to support BHA's long-term | during the month of August. If no additional | | | | | was well | |
| | | | Vue.JS, and development of a | reliable help and support, as well as | ownership of Calculator 3.0 - Completed | needs are identified, IV&V will close this finding. | | | | | received. | |
| | | | process to remain current on | much take a proactive approach to | | 06/30/2020 - The project continued to focus | | | | | | |
| | | | vulnerabilities discovered by the | security and identifying any | | attention on the Calculator 3.0 defects during | | | | | | |
| | | | support community. | vulnerabilities in the tools. | | the month of June. RSM conducted another | | | | | | |
| | | | - The RSM lead for Calculator 3.0 | | | Calculator 3.0 Knowledge Transfer session on | | | | | | |
| | | | went on extended parental leave | | | 6/26/2020 and scheduled a final session for | | | | | | |
| | | | in December 2019 | | | 7/17/2020. | | | | | | |
| | | | IV&V acknowledges that BHA has | | | | | | | | | |
| | | | downloaded Vue.JS to start | | | 05/31/2020 - The project continued to focus | | | | | | |
| | | | getting familiar with it. | | | attention on the Calculator 3.0 user stories and | | | | | | |
| | | | | | | defects during the month of May. RSM | | | | | | |
| | | | | | | conducted another Calculator 3.0 Knowledge | | | | | | |
| | | | | | | Transfer session on 5/29/2020 which IV&V | | | | | | |
| | | | | | | attended. This session included the new C3.0 | | | | | | |
| | | | | | | year-end changes. Additional KT sessions is | | | | | | |
| | | | | | | , , | | | | | | |
| 5.000 | 1/31/2020 | Due to the project not following a | There have been several defects | A complete, up to date, and | IVV recommends documenting | 12/31/2020 - IV&V has closed this issue as the | Release/Deployme | Issue | Medium | Closed | Key finding | D |
| 5.000 | 1/31/2020 | detailed deployment script, the | pushed to production with Phase | documented deployment script is | deployment scripts for both the patch | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been | Release/Deployme nt Planning | Issue | Medium | Closed | has been | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to | pushed to production with Phase 3 releases. Some of the defects | documented deployment script is needed to ensure the repeatability | deployment scripts for both the patch method and the full solution upgrade | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding | | Issue | Medium | Closed | has been addressed | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have | documented deployment script is needed to ensure the repeatability and stability of DOH's production | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing | | Issue | Medium | Closed | has been addressed and | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution | | Issue | Medium | Closed | has been addressed and proposed | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. | | Issue | Medium | Closed | has been addressed and proposed IV&V | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have been | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have been completed. A | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have been completed. A subsequent | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have been completed. A subsequent finding #19 | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have been completed. A subsequent finding #19 has been | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have been completed. A subsequent finding #19 has been created to | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have been completed. A subsequent finding #19 has been created to address on- | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have been completed. A subsequent finding #19 has been created to address ongoing | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have been completed. A subsequent finding #19 has been created to address ongoing deployment | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have been completed. A subsequent finding #19 has been created to address ongoing | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have been completed. A subsequent finding #19 has been created to address ongoing deployment processes | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have been completed. A subsequent finding #19 has been created to address ongoing deployment processes and | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have been completed. A subsequent finding #19 has been created to address ongoing deployment processes and technical | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have been completed. A subsequent finding #19 has been created to address ongoing deployment processes and technical execution | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for deployment | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have been completed. A subsequent finding #19 has been created to address ongoing deployment processes and technical execution | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for deployment | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. 10/31/2020 - The RSM and DOH Teams have | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have been completed. A subsequent finding #19 has been created to address ongoing deployment processes and technical execution | D Macdonald |
| 5.000 | 1/31/2020 | detailed deployment script, the project may continue to experience defects related to | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for deployment | documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when | deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. 10/31/2020 - The RSM and DOH Teams have collaborated to develop a detailed Production | | Issue | Medium | Closed | has been addressed and proposed IV&V recommend ations have been completed. A subsequent finding #19 has been created to address ongoing deployment processes and technical execution | D Macdonald |

| 6.000 | 1/31/2020 | 'Definition of Done", which could challenge the project's ability to fully achieve the goals of Phase 3. | 'Definition of Done' (DOD) for the BHA Top 100 User Stories of for Phase 3. Because of this, it is unclear how proposed functionality/features are prioritized for each sprint, and throughout Phase 3. | The 'Definition of Done" document guides the Project's vision, business, and technical goals that are important inputs for stakeholders to develop a Roadmap for Phase 3. Without the 'Definition of Done' document, the project is likely to struggle to prioritize proposed functionality/features which may be equally important but are at odds with each other. | recommends that the project create this document and socialize this with project team before end of Feb 2020 IV&V recommends that the project consider the items from the prioritized list, available resources and define | 02/29/2020 - The project created and documented the Phase 3 Definition of Done and socialized it in February. IV&V recommends the project continually review and update the Definition of Done, adjusting as/if necessary. IV&V will continue to monitor the project's adherence to Definition of Done and progress against it but is closing out this concern as of the February report. | Project Management | Concern | N/A | Closed | Definition of Done completed and socialized. | V Ramesh |
|-------|-----------|--|---|--|---|---|-----------------------|---------|-----|--------|---|----------------|
| 7.000 | 1/31/2020 | grooming could result in the project backlog having obsolete, non-estimated, and poorly defined user stories. | and user stories continues to grow. Currently, there are approximately 429 defects and requests, of which almost 200 have a status of 'New'. IVV notes | A comprehensive, up-to-date backlog is a primary tenet of agile software development. If a backlog is carrying work items that may not ever be completed for any reason, they should be removed from the backlog to ensure its viability. | IVV recommends that CAMHD and DDD groom the backlog to bring it as current and accurate as possible. This should include deprecating items no longer needed, and fully defining those items that are not yet fully defined, readying them for configuration or developer resources. To the extent feasible, BHA should involve RSM SMEs in this process, if only for the interim to get "caught up" on grooming efforts. (Closed) VV recommends that the project consider utilizing an age-based methodology for the deprecation of 'older' user stories in the backlog that may no longer be applicable or needed by the Product Owners and developing a process for periodic cleansing of the backlog using the same methodology. (Closed) | 06/30/2020 - IV&V has observed for another month that the project continues to groom the backlog. As a result, we are closing this finding. 05/31/2020 - The project team has determined the backlog grooming effort has caught up, as details for release 3.9 are completed and 3.10 is near completion. IV&V will keep this finding open for an additional month to validate that the backlog continues to be groomed as new stories and defects are identified. Efforts to keep the backlog groomed should take place each month so that release planning efforts are not delayed. 04/30/2020 - The project reported that 97% of the original backlog has been estimated at this time. That said, CAMHD has determined that there are several older, and possibly no longer necessary user stories in the backlog that are candidates for deletion. IV&V will keep this finding open and will re-assess it for impact during the month of May. 03/31/2020 - IV&V validates that the backlog grooming effort has made great progress, however it is still in progress. The revised target date for completion was most recently | Project Management | Risk | Low | Closed | The project has demonstrate d they are consistently grooming the backlog. | D Macdonald |

| 8.000 | 1/31/2020 | bandwidth may not be sufficient to meet the needs of the project, which could compromise project productivity. | available bandwidth. IV&V notes that BHA began addressing this bandwidth issue, which includes increased collaboration with key RSM resources, and are working to potentially change the | efforts of all technical DOH staff on the project. As such, the Team's time is both extremely valuable and scarce. If the Team's expected workload exceeds bandwidth, the project could experience bottlenecks. Optimization of the BHA Technical Team's time is to the benefit of the project and plays a critical role in the project's ability to hit performance targets and achieve the Phase 3 definition of done. | of the BHA Technical Team, either by adding resources through new hires, or vendor contracts. The Project should assess, where possible, if there are responsibilities of the BHA Technical Team that can be reassigned to other project staff. The Project should evaluate where process inefficiencies can be addressed and streamlined to possibly free up the BHA Technical Team's availability. | 03/31/2021 - BHA continued to take on more lead responsibilities in the areas of user story ownership and performing code reviews during the month of March. CAMHD is hopeful their open IT Technical position will be posted in April. IV&V will continue to monitor this finding. 02/28/2021 - Due to lack of administrative approvals, the internal BHA efforts to post and fill technical positions have slowed. CAMHD is hopeful that the open IT Technical position will be posted in March. IV&V will continue to monitor. 01/31/2021 - Due to internal DOH processes, the recruiting announcement for CAMHD's open IT Technician position was delayed until February. IV&V will continue to monitor this finding. IV&V notes that the RSM Team continued to provide essential support during January, alleviating some of the bandwidth concerns expressed by DOH to meet crucial project needs. Due to RSM resource levels being significantly reduced in March, the balance of agile releases will also be reduced in scope. 12/31/2020 - BHA stated that although most vacant positions cannot be filled at this time, they have approval to fill a vacant IT Technician | Sprint Planning | Risk | Medium | Open | | D Macdonald |
|-------|-----------|--|---|--|--|---|-----------------------|---------|--------|------|---|----------------|
| 9.000 | 1/31/2020 | that provides direction on the top product features to be delivered in the near term (next 3 months), midterm, and long term could have an adverse impact on the Project's scope and schedule. | Phase 3 that addresses the functionalities, features, and / or enhancements to be built in order to fully address BHA's business needs. IV&V met with RSM and BHA on this topic in January, and notes that the project is actively working to address this concern. | A Roadmap is a tool that guides an agile project on what functionalities/features are targeted to be built and released and when users can have access to these functionalities. Without a defined Roadmap the project may not be able to effectively scope the top features to be released within Phase 3 and ensure the correct resources are available to accomplish the goal of each sprint and the Phase. | IV&V understands that the Project is in the process of creating a Short Term; Mid Term, and Long Term Roadmap. IV&V recommends the Project complete this by the end of February 2020 to understand if there are any constraints (resources, budget) that may hinder the project from releasing the needed functionalities/features targeted for Phase 3 as documented in the Definition of Done. | 02/29/2020 - In February, the project further defined the Phase 3 Product Roadmap and aligned it with the Phase 3 Definition of Done. IV&V recommends the project continually review and update both the Product Roadmap and Definition of Done, adjusting as necessary. IV&V will continue to monitor the project's adherence to the Product Roadmap and progress against it but is closing out this concern as of the February report. | Project Management | Concern | N/A | | Product Roadmap aligned with Definition of Done | V Ramesh |

| 10.000 | 3/31/2020 | The COVID-19 pandemic and the | On 3/23/2020, the Governor | DOH stakeholder participation in | - IV&V recommends BHA to ramp up | 03/31/2021 - The Project continued to maintain | Project | Risk | Low | Open | D | |
|--------|-----------|--|---|---|--|---|------------|---------|-----|--------|---|----------|
| | | related "stay at home" order could hinder project activities and negatively impact the project schedule and budget. | issued a "stay at home, work from home order" that has reduced state departments ability to be fully functional as the large majority of state workers will be required to work from home/remotely at least until the end of April and some offices may be completely shut down until that time as well. Unclear if the order will extend beyond that date. | key activities could be significantly hindered, not only by required remote work by DOH and SI staff, but also by the flood of activities that could occur as the department could become overwhelmed processing and providing services due to the resulting economic impacts to citizens. Some stakeholders may be unable (due to stricter shutdown policies) or unwilling to perform these activities during this chaotic time. Planned SI on-site visits will also likely be changed to remote which could reduce the effectiveness of their project activities. Going forward most if not all project | efforts to setup, train, and assist stakeholders on remote work devices and tools and make every effort to help them to become highly functional with remote access technology (e.g. MS Teams/Skype) - Completed - IV&V recommends the project and DOH create a detailed, documented risk mitigation strategy and plan that is reviewed regularly and revised to address the current state of the COVID-19 threat and related impacts over the next 6 to 12 months - In Progress | its ability to operate with staff working remotely, while COVID-related responsibilities continue to grow for CAMHD Leadership. The Governor announced that potential furloughs and/or layoffs of State workers will no longer be necessary based on the signing of the American Rescue Plan. IV&V has reduced the priority of this finding from Medium to Low and will continue to monitor moving forward. 02/28/2021 - As reported in January, there were no substantive changes observed for this finding in February. The Project continued to maintain its ability to operate with staff working remotely. IV&V continues to note that there may be potential future budget actions by the Governor due to projected State budget shortfalls, including furloughs that are planned to be re-evaluated in July. If realized, these actions could have negative effects on project funding. 01/31/2021 - No substantive changes were observed in January. The project continued to maintain its ability to operate with staff working remotely. As previously reported, key project staff continue to have responsibility for participating in non-project activities to support | Management | | | | Ma | acdonald |
| 11.000 | 5/31/2020 | The lack of design reviews for complex user stories has resulted in the promotion of incomplete solutions into production. | during May where the code promoted to production did not fully meet all requirements of associated user stories for | collection and potential issues in | design reviews for complex user stories prior to development to ensure designs are complete and all requirements | 07/31/2020 - The Project continues to to spend additional time on the designs of complex user stories during June to ensure requirements and user story components were fully captured in design sessions. This process change has proven successful, and as such, IV&V recommends closing this concern. 06/30/2020 - IV&V acknowledges the Project Team continued to spend additional time on the designs of complex user stories during June to ensure requirements and user story components were fully captured in design sessions. IV&V will continue to monitor in July. | | Concern | | Closed | This process change to spend extra time on the design of complex user stories to ensure that all requirement s are represented has proven to be successful. | |

| 12.000 | 7/31/2020 | DDD Project resource shortages | The user adoption and training | The significance and impact of OCM | IV&V recommends that BHA does as | 03/31/2021 - The DDD staff who've been part of | Project | Risk | Low | Closed | The DDD | D |
|--------|-----------|------------------------------------|--|--|---|--|------------|-------|--------|--------|---------------|-----------|
| 12.000 | //31/2020 | may have a continued negative | efforts are hampered based on | can never be understated. It is | much as possible within its sphere of | · · · · · · · · · · · · · · · · · · · | Management | Misk | LOW | Cioseu | staff who've | _ |
| | | effect on user adoption, training, | staffing shortages. DDD has | | influence to increase user adoption and | of the videos produced within the toolset and | Wanagement | | | | been part of | Macaonara |
| | | and overall OCM activities. | stated that its users have been | all staff utilize the solution in the | training. This includes procurement of | have determined that the toolset is a very | | | | | the review | |
| | | and over all o'en accivities. | found to not be utilizing the | same manner. Variations in how | the online training toolsets to offset the | helpful training tool for DDD staff and providers. | | | | | process are | |
| | | | system to its fullest extent in | the system is utilized by its users is | need for in-person training, and adding | As such, IV&V is closing this finding. | | | | | pleased with | |
| | | | terms of system workflow, | | staff as needed to support OCM and | 02/28/2021 - Training videos using the new | | | | | the quality | |
| | | | provide their insights and input, | collection and analytical efforts | technical efforts. | toolset were nearing completion by the end of | | | | | of the videos | |
| | | | follow up, etc. To assist in OCM | | IV&V recommends DOH perform a | February. DOH is currently reviewing the drafts | | | | | produced | |
| | | | activities, DDD has defined the | | detailed investigation of the specific | of the second set of videos and work is | | | | | within the | |
| | | | need for an interactive training | | variations as to how the system is | progressing well. IV&V will continue to monitor | | | | | toolset, and | |
| | | | tool to support Inspire. | | currently being used by the user | this finding until DDD has had sufficient time to | | | | | have | |
| | | | | | community. Consequently, users would | determine the overall quality of the training | | | | | determined | |
| | | | | | be provided with constructive feedback | work products and whether the new toolset is | | | | | that the | |
| | | | | | on how the system should be utilized | addressing user adoption and staffing shortages | | | | | toolset is a | |
| | | | | | where gaps exist. This will likely lead to | for these task efforts. | | | | | very helpful | |
| | | | | | additional refresher training to close | 01/31/2021 - Training design activities using the | | | | | training tool | |
| | | | | | identified system knowledge gaps. | interactive training toolset commenced in | | | | | for DDD | |
| | | | | | | January and has attained good progress. The use | | | | | staff and | |
| | | | | | | of this tool is expected to provide some | | | | | providers. | |
| | | | | | | bandwidth relief for DDD staff members | | | | | | |
| | | | | | | responsible for onboarding new staff members | | | | | | |
| | | | | | | and providers, and to provide refresher training | | | | | | |
| | | | | | | to existing staff members. IV&V will continue to | | | | | | |
| | | | | | | monitor this finding | | | | | | |
| | | | | | | 12/31/2020 - The contract to procure the | | | | | | |
| | | | | | | interactive training toolset for onboarding new | | | | | | |
| 13.000 | 8/31/2020 | PII/PHI data in non-production | IV&V has been made aware that | · · | IV&V recommends if production data is | 03/31/2021 - There were no substantive | Project | Issue | Medium | Open | | D |
| | | environments | PII/PHI data currently exist in a | the organization open to highly | necessary in any non-production | changes for this finding in March. Due to | Management | | | l | | Macdonald |
| | | | non-production environment to | targeted social engineering attacks, | environment that DOH establishes a plan | resource constraints, establishing a plan for | | | | l | | |
| | | | meet project needs. Generally | heavy regulatory fines, and loss of | for effectively managing the security of | managing PHI/PII data in non-production DOH | | | | l | | |
| | | | this is not a good security practice | client trust and loyalty. | the PII/PHI data, including the potential | environments has not yet commenced. Based on | | | | l | | |
| | | | as the presence of PII/PHI data in | | masking of data. | continued delays, it remains unclear when this | | | | l | | |
| | | | non-production environments | | IV&V recommends that DOH mitigates | important security mitigation activity will be | | | | l | | |
| | | | increases the potential for theft, | | this finding by removing and/or masking any PHI/PII data in its non-production | completed. IV&V has raised the priority of this | | | | ł . | | |
| | | | loss or exposure thus increasing | | | | | | | | | |
| | | | the organization's risk Eailure to | | 1 ' ' ' | finding from a Low Risk to a Medium Issue due | | | | ļ | | |
| | | | the organization's risk. Failure to | | environments. | to delays in resolving this finding. IV&V will | | | | | | |
| | | | secure PII/PHI data leaves the | | environments. NEW - IV&V recommends DOH consider | to delays in resolving this finding. IV&V will continue to monitor. | | | | | | |
| | | | secure PII/PHI data leaves the organization open to highly | | environments. NEW - IV&V recommends DOH consider limiting the volume of environments and | to delays in resolving this finding. IV&V will continue to monitor. 02/28/2021 - There were no substantive | | | | | | |
| | | | secure PII/PHI data leaves the organization open to highly targeted social engineering | | environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support | to delays in resolving this finding. IV&V will continue to monitor. 02/28/2021 - There were no substantive changes for this finding in February. BHA is | | | | | | |
| | | | secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, | | environments. NEW - IV&V recommends DOH consider limiting the volume of environments and | to delays in resolving this finding. IV&V will continue to monitor. 02/28/2021 - There were no substantive changes for this finding in February. BHA is establishing a plan for managing its PHI/PII data | | | | | | |
| | | | secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and | | environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development work, which should help | to delays in resolving this finding. IV&V will continue to monitor. 02/28/2021 - There were no substantive changes for this finding in February. BHA is establishing a plan for managing its PHI/PII data in non-production environments. Based on | | | | | | |
| | | | secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, | | environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development work, which should help | to delays in resolving this finding. IV&V will continue to monitor. 02/28/2021 - There were no substantive changes for this finding in February. BHA is establishing a plan for managing its PHI/PII data | | | | | | |
| | | | secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and | | environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development work, which should help | to delays in resolving this finding. IV&V will continue to monitor. 02/28/2021 - There were no substantive changes for this finding in February. BHA is establishing a plan for managing its PHI/PII data in non-production environments. Based on continued delays, it is unclear when this | | | | | | |
| | | | secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and | | environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development work, which should help | to delays in resolving this finding. IV&V will continue to monitor. 02/28/2021 - There were no substantive changes for this finding in February. BHA is establishing a plan for managing its PHI/PII data in non-production environments. Based on continued delays, it is unclear when this important security activity will be completed. | | | | | | |
| | | | secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and | | environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development work, which should help | to delays in resolving this finding. IV&V will continue to monitor. 02/28/2021 - There were no substantive changes for this finding in February. BHA is establishing a plan for managing its PHI/PII data in non-production environments. Based on continued delays, it is unclear when this important security activity will be completed. 01/31/2021 - No substantive changes were | | | | | | |
| | | | secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and | | environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development work, which should help | to delays in resolving this finding. IV&V will continue to monitor. 02/28/2021 - There were no substantive changes for this finding in February. BHA is establishing a plan for managing its PHI/PII data in non-production environments. Based on continued delays, it is unclear when this important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of | | | | | | |
| | | | secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and | | environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development work, which should help | to delays in resolving this finding. IV&V will continue to monitor. 02/28/2021 - There were no substantive changes for this finding in February. BHA is establishing a plan for managing its PHI/PII data in non-production environments. Based on continued delays, it is unclear when this important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. | | | | | | |
| | | | secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and | | environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development work, which should help | to delays in resolving this finding. IV&V will continue to monitor. 02/28/2021 - There were no substantive changes for this finding in February. BHA is establishing a plan for managing its PHI/PII data in non-production environments. Based on continued delays, it is unclear when this important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in | | | | | | |
| | | | secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and | | environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development work, which should help | to delays in resolving this finding. IV&V will continue to monitor. 02/28/2021 - There were no substantive changes for this finding in February. BHA is establishing a plan for managing its PHI/PII data in non-production environments. Based on continued delays, it is unclear when this important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is completed. IV&V | | | | | | |
| | | | secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and | | environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development work, which should help | to delays in resolving this finding. IV&V will continue to monitor. 02/28/2021 - There were no substantive changes for this finding in February. BHA is establishing a plan for managing its PHI/PII data in non-production environments. Based on continued delays, it is unclear when this important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is completed. IV&V will continue to monitor this finding. | | | | | | |
| | | | secure PII/PHI data leaves the organization open to highly targeted social engineering attacks, heavy regulatory fines, and loss of client trust and | | environments. NEW - IV&V recommends DOH consider limiting the volume of environments and access necessary to support development work, which should help | to delays in resolving this finding. IV&V will continue to monitor. 02/28/2021 - There were no substantive changes for this finding in February. BHA is establishing a plan for managing its PHI/PII data in non-production environments. Based on continued delays, it is unclear when this important security activity will be completed. 01/31/2021 - No substantive changes were observed in January. BHA is still in the process of establishing a plan for managing PHI/PII data. This effort remains anticipated to commence in February, after Release 3.12 is completed. IV&V will continue to monitor this finding. 12/31/2020 - BHA is still in the process of | | | | | | |

| 14.000 | 8/31/2020 | Project not able to access Activity | The Project recently deployed | The unavailability of activity logs | IV&V recommends that DHS continues to | 03/31/2021 - Per BHA, this finding is no longer | Release/Deployme | Risk | Low | Closed | Finding has | D |
|--------|-------------|--|--|--|--|---|------------------|-------|--------|--------|-------------|-----------|
| | | Logs | audit log functionality into | may hamper the investigation of | collaborate with Microsoft until the | an issue and recommends closure. IV&V is | nt Planning | | | | been | Macdonald |
| | | | production whereby these logs | future security breaches. | activity logging feature is available in all | closing this finding. | | | | | resolved. | |
| | | | can be accessed and exported as | | BHA non-production environments. | 02/28/2021 - BHA continued this effort in | | | | | | |
| | | | needed. However, IV&V was | | | February despite a workaround being necessary | | | | | | |
| | | | made aware access to activity | | | from Microsoft due to a layering issue. Based on | | | | | | |
| | | | logging for users with just view | | | continued delays, it is unclear when this | | | | | | |
| | | | permissions will not be available | | | important security activity will be completed. | | | | | | |
| | | | from Microsoft in the public | | | IV&V will continue to monitor this finding. (Per | | | | | | |
| | | | sector environment until the end | | | Kamu, this status information did not correctly | | | | | | |
| | | | of September 2020. The | | | reflect the issue as the layering issue has no | | | | | | |
| | | | unavailability of these specific | | | relation to the activity logs.) | | | | | | |
| | | | activity logs could potentially | | | 01/31/2021 - The implementation effort for this | | | | | | |
| | | | hamper the investigation of | | | activity moved forward in January. Some of the | | | | | | |
| | | | future security events until | | | entities will have activity logging completed in | | | | | | |
| | | | implemented. | | | the planned early February Release 3.12, while | | | | | | |
| | | | | | | others will be delayed until Release 3.13. IVV | | | | | | |
| | | | | | | will continue to monitor. | | | | | | |
| | | | | | | 12/31/2020 - The planning effort for identifying | | | | | | |
| | | | | | | the entities that will require activation of the | | | | | | |
| | | | | | | new activity logs was completed during | | | | | | |
| | | | | | | December. The implementation effort has been | | | | | | |
| | | | | | | prioritized for inclusion in Release 3.12. IV&V | | | | | | |
| | | | | | | will continue to monitor this finding until | | | | | | |
| | | | | | | implemented. | | | | | | |
| | | | | | | 11/30/2020 - The DOH technical team has commenced the analytical effort to determine | | | | | | |
| 15 000 | 0 /20 /2020 | Don't a model of a mod | Contain defeate identified in | The identified quality issues have | To address quality issues, the Project | , | Project | Issue | High | Open | | D |
| 15.000 | 9/30/2020 | Due to multiple quality concerns, | System defects identified in | | | | | | | | | |
| | | the project may continue to face | 1 ' | | | 03/31/2021 - R3.13 was promoted to production | 1 ' | 13300 | 111611 | Орен | | Macdonald |
| | | the project may continue to face | August that affected claims were | negatively affected DOH billing | should continue to pursue and/or | on 3/14/2021. The RCA based upon R3.12 was | Management | 13300 | 111611 | Орен | | Macdonald |
| | | the project may continue to face impactful system defects. | August that affected claims were due to multi-faceted quality | negatively affected DOH billing processes and DOH has stated | should continue to pursue and/or consider: | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in | 1 ' | 13300 | 111811 | Орен | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually | negatively affected DOH billing processes and DOH has stated these are the most impactful | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as | 1 ' | 13340 | 111611 | Орен | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting | negatively affected DOH billing processes and DOH has stated | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, | 1 ' | 13300 | | Орен | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is | negatively affected DOH billing processes and DOH has stated these are the most impactful | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. | 1 ' | 13300 | 111511 | Орен | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being | negatively affected DOH billing processes and DOH has stated these are the most impactful | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be | 1 ' | 13300 | 111511 | Орен | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited | negatively affected DOH billing processes and DOH has stated these are the most impactful | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but | 1 ' | 13300 | | Орен | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the | negatively affected DOH billing processes and DOH has stated these are the most impactful | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the | 1 ' | 13300 | | Орен | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with | negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date. | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the identified action plan items are considered as | 1 ' | 13300 | | Орен | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project | negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date. | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the identified action plan items are considered as potentially easy to implement. IV&V will | 1 ' | 13300 | | Орен | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with | negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date. | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the identified action plan items are considered as | Management | 13300 | | Среп | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of | negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date. | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the identified action plan items are considered as potentially easy to implement. IV&V will continue to monitor. | Management | 13300 | | Среп | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to | negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date. | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the identified action plan items are considered as potentially easy to implement. IV&V will continue to monitor. 02/28/2021 - R3.12 was promoted to production | Management | 13300 | 11161 | Gpen | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. | negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date. | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the identified action plan items are considered as potentially easy to implement. IV&V will continue to monitor. 02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new | Management | 13300 | 1161 | Gpen | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: | negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date. | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the identified action plan items are considered as potentially easy to implement. IV&V will continue to monitor. 02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these | Management | 13300 | 1161 | Gpen | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality | negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date. | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the identified action plan items are considered as potentially easy to implement. IV&V will continue to monitor. 02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving | Management | 13300 | 1161 | Gpen | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected | negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date. | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the identified action plan items are considered as potentially easy to implement. IV&V will continue to monitor. 02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required | Management | 13300 | 1161 | Open | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely | negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date. | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the identified action plan items are considered as potentially easy to implement. IV&V will continue to monitor. 02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. | Management | 13300 | 1181 | Среп | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to | negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date. | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for effectiveness In Progress | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the identified action plan items are considered as potentially easy to implement. IV&V will continue to monitor. 02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to | Management | 13300 | 1181 | Среп | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. | negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date. | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for effectiveness In Progress 6) Evaluate existing project staff skills | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the identified action plan items are considered as potentially easy to implement. IV&V will continue to monitor. 02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure | Management | 13300 | 1161 | Cpen | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. | negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date. | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for effectiveness In Progress 6) Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements - Open 7) IV&V recommends performing an RCA | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the identified action plan items are considered as potentially easy to implement. IV&V will continue to monitor. 02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. | Management | 13300 | 1181 | Open | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release | negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date. | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for effectiveness In Progress 6) Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements - Open 7) IV&V recommends performing an RCA in collaboration with RSM after all future | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the identified action plan items are considered as potentially easy to implement. IV&V will continue to monitor. 02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in | Management | 13300 | 1161 | Open | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. | negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date. | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for effectiveness In Progress 6) Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements - Open 7) IV&V recommends performing an RCA | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the identified action plan items are considered as potentially easy to implement. IV&V will continue to monitor. 02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. | Management | 13300 | 1161 | Среп | | Macdonald |
| | | 1 ' ' | August that affected claims were due to multi-faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release | negatively affected DOH billing processes and DOH has stated these are the most impactful defects discovered to date. | should continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for effectiveness In Progress 6) Evaluate existing project staff skills and experience level to ensure they meet BHA support requirements - Open 7) IV&V recommends performing an RCA in collaboration with RSM after all future | on 3/14/2021. The RCA based upon R3.12 was completed in March which resulted in recommendations that were categorized as Coding Errors, Deployment, Design Errors, Microsoft Issues, and Requirement Errors. Resulting Action Plans were expected to be finalized and prioritized at the end of March but have now been pushed to April. Several of the identified action plan items are considered as potentially easy to implement. IV&V will continue to monitor. 02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required a fix to production on 2/25/2021. BHA initiated an RCA for the R3.12 defects to help with quality improvement and to ensure these same issues do not recur in future releases. Completion of the RCA is expected in early March. | Management | 13300 | 1181 | Среп | | Macdonald |

| 16.000 | 10/5/2020 | Licens of Computing and IDNA for | The preject peter its intent to | | | 01/21/2021 The preject has made great strides | Taxaatad I/T | Concern | | Classed | The success | D |
|--------|------------|--|---|--|---|--|-----------------------|---------|--------|---------|--------------|----------------|
| 16.000 | 10/5/2020 | Usage of Semantics and IDM for | The project noted its intent to | | | 01/31/2021 - The project has made great strides | Targeted KT | Concern | | Closed | - 13 | |
| | | development and ongoing | obtain more targeted knowledge | | | addressing this concern. A Semantics Layer KT | | | | | | Macdonald |
| | | maintenance of the system | transfer of both the Semantics | | | session was conducted on 1/29/21 and multiple | | | | | good | |
| | | requires BHA to take a proactive | Reporting and IDM tools. IV&V | | | IDM and Semantic Layer sessions has been | | | | | progress | |
| | | approach to support of these | will continue to monitor this | | | scheduled in February. IV&V is closing this | | | | | establishing | |
| | | tools. | concern. | | | finding as we no longer view this item as a | | | | | and initial | |
| | | | | | | concern. | | | | | execution of | |
| | | | | | | 12/31/2020 - IV&V is aware that an overview of | | | | | the IDM and | |
| | | | | | | the Semantics Layer KT session was held on | | | | | Semantics | |
| | | | | | | 12/16/20. The planning effort will result in | | | | | Layer KT | |
| | | | | | | additional Semantic Layer and IDM KT sessions | | | | | plan. | |
| | | | | | | in the coming months. IV&V will continue to | | | | | | |
| | | | | | | monitor this finding. | | | | | | |
| | | | | | | 11/30/2020 - The project conducted two high- | | | | | | |
| | | | | | | level overview sessions of the Semantic Layer | | | | | | |
| | | | | | | Reporting tools during November. One session | | | | | | |
| | | | | | | was focused on the overall Semantic Layer, and | | | | | | |
| | | | | | | the second session was focused on Semantic | | | | | | |
| | | | | | | Layer Security. Additional targeted Knowledge | | | | | | |
| | | | | | | Transfer sessions on the Semantic Layer tools | | | | | | |
| | | | | | | will need to be provided by RSM; however, | | | | | | |
| | | | | | | these have not been scheduled. IV&V will | | | | | | |
| | | | | | | continue to monitor this finding. | | | | | | |
| | | | | | | 10/31/2020 - The project intends to obtain more | | | | | | |
| | | | | | | targeted knowledge transfer for both the | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | Semantics Reporting and IDM tools and will be planning and scheduling these sessions with the | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| 17.000 | 10/27/2020 | The bandwidth of CAMHD | CAMHD has been provided with | CAMDH Leadership participation in | IV&V recommends CAMHD look for | 03/31/2021 - CAMHD Leadership time spent on | Project | Risk | Medium | Open | | D |
| 17.000 | 10/27/2020 | Leadership is being hampered by | an approval to commence | key activities could be significantly | opportunities to augment the | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued | Project Management | Risk | Medium | Open | | D Macdonald |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for | an approval to commence planning efforts for expansion of | key activities could be significantly hindered by the flood of activities | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD | key activities could be significantly hindered by the flood of activities that could occur as the department | opportunities to augment the | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their | key activities could be significantly hindered by the flood of activities that could occur as the department | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. 02/28/2021 - CAMHD Leadership continued to | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. 02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. 02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. 02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. 02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. 02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. 02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. 02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. 02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. 02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. 02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. 02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. 02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. 02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. The level of dedication to this effort is certain to continue to increase in the coming months. | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. 02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. 12/31/2020 - The planning effort for the | ' | Risk | Medium | Open | | _ |
| 17.000 | 10/27/2020 | Leadership is being hampered by planning tasks and activities for assessing project expansion to | an approval to commence planning efforts for expansion of the project for ADAD and AMHD & HSH. CAMHD Leadership currently spends 25% of their available time dedicated to this | key activities could be significantly hindered by the flood of activities that could occur as the department assesses expansion of this project | opportunities to augment the management staffing for planning Phase | 03/31/2021 - CAMHD Leadership time spent on efforts outside of the INSPIRE Project continued to increase during March. More than 50% of Leadership time is spent on Phase 4 Planning and COVID Remediation efforts. The level of dedication to this effort is likely to continue to increase in the coming months. IV&V has raised the priority of this finding from Low to Medium and will continue to monitor moving forward. 02/28/2021 - CAMHD Leadership continued to spend upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. IV&V will continue to monitor this finding. 01/31/2021 - The CAMHD Leadership is now spending upwards of 1/3 of available time in the planning effort for Phase 4 of the Project, which is intended to expand the D365 solution to the remaining DOH divisions. The level of dedication to this effort is certain to continue to increase in the coming months. The level of dedication to this effort is certain to continue to increase in the coming months. | ' | Risk | Medium | Open | | _ |

| 18.000 | 11/30/2020 | Due to consistent technical issues | The IDM and Semantic layer | | IV&V recommends the project to | 03/31/2021 - BHA continues to work with | Release/Deployme | Issue | High | Open | ln l |
|--------|------------|---|--|---|--|---|---------------------------------|-------|------|------|----------------|
| 20.000 | 11,30,2020 | requiring escalation to Microsoft, | efforts have experienced several | | continue to monitor the status of | Microsoft on technical issues as they arise in the | nt Planning | 15540 | | Орен | Macdonald |
| | | some project efforts are being | delays attributable to issues | | outstanding Microsoft tickets and to | Government Community Cloud (GCC) instance. | | | | | |
| | | delayed. | escalated to Microsoft. The | | escalate the priority of these tickets as | The issue with fields being locked is still | | | | | |
| | | | issues have ranged from | | deemed necessary. | outstanding. IV&V will continue to monitor this | | | | | |
| | | | administrative / communication | | · · | finding. | | | | | |
| | | | (entering issues into the | | | 02/28/2021 - BHA continues to work with | | | | | |
| | | | Commercial support instance vs | | | Microsoft on technical issues as they arise in the | | | | | |
| | | | the Government Cloud support | | | Government Community Cloud (GCC) instance. | | | | | |
| | | | instance), to several key technical | | | IV&V will continue to monitor this finding. | | | | | |
| | | | issues requiring assistance to | | | 01/31/2020 - While most of the Microsoft issues | | | | | |
| | | | resolve. To date, these support | | | were fixed, the 'first 10 rows', the 'multi-select | | | | | |
| | | | needs have added over a month | | | options', and 'unmanaged layer on the Case | | | | | |
| | | | to the IDM and Semantic Layer | | | entity' issues are partially outstanding impacting | | | | | |
| | | | project schedules. | | | project timelines. As temporary measures, the | | | | | |
| | | | | | | project has developed workarounds. Per BHA, | | | | | |
| | | | | | | the Product Roadmap for the GCC product | | | | | |
| | | | | | | continues to lag behind commercial instances | | | | | |
| | | | | | | which causes uncertainties for the BHA-ITS | | | | | |
| | | | | | | Project. BHA plans to meet with senior | | | | | |
| | | | | | | Microsoft management to discuss during | | | | | |
| | | | | | | February. IV&V will continue to monitor. | | | | | |
| | | | | | | 12/31/2020 - While most of the issues requiring | | | | | |
| | | | | | | escalation to Microsoft were adequately | | | | | |
| | | | | | | addressed during December, the Azure Data | | | | | |
| | | | | | | Factory (ADF) 'first 10 rows missing data' issue | | | | | |
| | | | | | | | | | | | |
| | | | | | | remain open. BHA has created a work around for | | | 1 | _ | _ |
| 19.000 | 12/31/2020 | Due to on-going deployment | There have been several defects | Repeatable documented release | Develop a plan to institutionalize the | 03/31/2021 - R3.13 was promoted to production | Release/Deployme | Issue | High | Open | D |
| 19.000 | 12/31/2020 | processes and technical execution | pushed to production with Phase | and deployment will help ensure | execution of "Smoke Testing" for | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis | Release/Deployme nt Planning | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue | pushed to production with Phase 3 releases. Some of the defects | and deployment will help ensure that mistakes are minimized, and | execution of "Smoke Testing" for promotions to non-production and | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and | pushed to production with Phase 3 releases. Some of the defects introduced to production have | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly | execution of "Smoke Testing" for promotions to non-production and production environments. This will help | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort has been pushed to April due to resource | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort has been pushed to April due to resource constraints. Initial efforts may include providing | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place. | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort has been pushed to April due to resource | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place. | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort has been pushed to April due to resource constraints. Initial efforts may include providing more details in the SharePoint and deployment | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place. | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort has been pushed to April due to resource constraints. Initial efforts may include providing more details in the SharePoint and deployment checklists coupled with a secondary review | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place. | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort has been pushed to April due to resource constraints. Initial efforts may include providing more details in the SharePoint and deployment checklists coupled with a secondary review process. BHA is considering the procurement of | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place. | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort has been pushed to April due to resource constraints. Initial efforts may include providing more details in the SharePoint and deployment checklists coupled with a secondary review process. BHA is considering the procurement of a tool(s) to aid with deployments/releases. This | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place. | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort has been pushed to April due to resource constraints. Initial efforts may include providing more details in the SharePoint and deployment checklists coupled with a secondary review process. BHA is considering the procurement of a tool(s) to aid with deployments/releases. This includes the administrative software tool | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place. | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze dates as well as test environment | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort has been pushed to April due to resource constraints. Initial efforts may include providing more details in the SharePoint and deployment checklists coupled with a secondary review process. BHA is considering the procurement of a tool(s) to aid with deployments/releases. This includes the administrative software tool demonstrated by RSM which manages the | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place. | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort has been pushed to April due to resource constraints. Initial efforts may include providing more details in the SharePoint and deployment checklists coupled with a secondary review process. BHA is considering the procurement of a tool(s) to aid with deployments/releases. This includes the administrative software tool demonstrated by RSM which manages the versions of software and components contained | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place. | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort has been pushed to April due to resource constraints. Initial efforts may include providing more details in the SharePoint and deployment checklists coupled with a secondary review process. BHA is considering the procurement of a tool(s) to aid with deployments/releases. This includes the administrative software tool demonstrated by RSM which manages the versions of software and components contained in all environments. IV&V will continue to | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place. | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort has been pushed to April due to resource constraints. Initial efforts may include providing more details in the SharePoint and deployment checklists coupled with a secondary review process. BHA is considering the procurement of a tool(s) to aid with deployments/releases. This includes the administrative software tool demonstrated by RSM which manages the versions of software and components contained in all environments. IV&V will continue to monitor this finding. | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for deployment | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place. | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. COMPLETED Request the assistance of the RSM Solution Architect in reviewing and | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort has been pushed to April due to resource constraints. Initial efforts may include providing more details in the SharePoint and deployment checklists coupled with a secondary review process. BHA is considering the procurement of a tool(s) to aid with deployments/releases. This includes the administrative software tool demonstrated by RSM which manages the versions of software and components contained in all environments. IV&V will continue to monitor this finding. 02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place. | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. COMPLETED Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort has been pushed to April due to resource constraints. Initial efforts may include providing more details in the SharePoint and deployment checklists coupled with a secondary review process. BHA is considering the procurement of a tool(s) to aid with deployments/releases. This includes the administrative software tool demonstrated by RSM which manages the versions of software and components contained in all environments. IV&V will continue to monitor this finding. 02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for deployment | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place. | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze dates as well as test environment deployment activities are not rushed. COMPLETED Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort has been pushed to April due to resource constraints. Initial efforts may include providing more details in the SharePoint and deployment checklists coupled with a secondary review process. BHA is considering the procurement of a tool(s) to aid with deployments/releases. This includes the administrative software tool demonstrated by RSM which manages the versions of software and components contained in all environments. IV&V will continue to monitor this finding. 02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving the workflow for progress notes which required | | Issue | High | Open | D Macdonald |
| 19.000 | 12/31/2020 | processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non- | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized by BHA for deployment | and deployment will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take place. | execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. As appropriate, consult with RSM on best practices that BHA could employ to support deployment. Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. COMPLETED Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with | 03/31/2021 - R3.13 was promoted to production on 3/14/2021. The R3.12 Root Cause Analysis (RCA) effort was completed in March resulting in several recommendations (some of which were in alignment with IV&V recommendations as listed below) for increasing the quality of deployments. Resulting action plans were expected to be finalized and prioritized by the end of March, however the prioritization effort has been pushed to April due to resource constraints. Initial efforts may include providing more details in the SharePoint and deployment checklists coupled with a secondary review process. BHA is considering the procurement of a tool(s) to aid with deployments/releases. This includes the administrative software tool demonstrated by RSM which manages the versions of software and components contained in all environments. IV&V will continue to monitor this finding. 02/28/2021 - R3.12 was promoted to production on 2/14/2021. Approximately thirteen new defects resulted from the release. One of these defects was a critical CAMHD defect involving | | Issue | High | Open | D Macdonald |

| 20.000 | 3/28/2021 | The pending RSM contract | The RSM contract for Phase 3 is | DOH needs to be in a position to | Work hand in hand with RSM to ensure | Project | Concern | ا ار | Open | Vic Dudoit |
|--------|-----------|--------------------------------|------------------------------------|-------------------------------------|--|------------|---------|------|------|------------|
| 20.000 | 3/20/2021 | ' " | | ' | | | Concern | | pen | VIC Dadoit |
| | | expiration will require BHA to | currently planned to complete in | | that DOH has the knowledge, skills, and | Management | | | | |
| | | perform transition of the D365 | September 2021. BHA will need a | | capabilities to perform all aspects of the | | | | | |
| | | solution to the State prior to | transition plan to ensure that it | support by fall of 2021. If DOH is | project prior to September 2021. If the | | | | | |
| | | contract end. | has all knowledge transfer and is | not in a position to solely take on | knowledge transfer takes more time | | | | | |
| | | | fully capable of managing all | the development of user stories, | than planned, consider developing, | | | | | |
| | | | aspects of supporting and | testing, regression testing, | testing, and promoting less releases in | | | | | |
| | | | maintaining the D365 solution | deployment, and the support and | the summer months as the transition off | | | | | |
| | | | without vendor support until at | maintenance of the entire system, | of vendor support approaches. | | | | | |
| | | | least the Phase 4 expansion effort | there is a risk that environment | | | | | | |
| | | | is procured and initiated. The | stability may be challenged. | | | | | | |
| | | | Phase 4 effort is currently | | | | | | | |
| | | | expected to commence late in the | | | | | | | |
| | | | 4th quarter of 2021, or early in | | | | | | | |
| | | | the first quarter of 2022. The | | | | | | | |
| | | | Phase 4 procurement scope is | | | | | | | |
| | | | planned to include additional | | | | | | | |
| | | | DD&I activities, as well as M&O | | | | | | | |
| | | | - | | | | | | | |
| | | | support activities. | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |